MARKET SIGNAL REPORT
POWERED BY STOCKSTOTRADE |
| WED OCT 28 CLOSE · AS OF 2:05 PM ET · SPY +0.17% QQQ +0.15% DIA +0.18% IWM +0.00% |
|
|
|
KEY TAKES
- The Fed held at 3.75% to 4.00%, as expected. Futures now put a December hike near 85% (CME via CNBC).
- Memory chips led after SK Hynix's profit jumped more than sevenfold: MU +4.4%, SOXX +1.2%. Megacaps lagged into Microsoft and Alphabet's after-the-bell reports: META -1.4%, TSLA -1.2%, MSFT -0.8%.
- Bloomberg says an Elon Musk-backed startup is heading for a blockbuster IPO; one analyst names it (From Brownstone Research)
- The real money moves were single-stock: Genmab on a cancer trial, Axogen on a beat, Ultralife on a cash deal.
|
|
The Fed held its rate at 3.75% to 4.00% at 2 PM ET, the call futures had priced at about 93% (CNBC). Nobody is treating it as relief. Futures put a December hike near 85%, Thursday's PCE is expected to show inflation rising to about 3.7%, and Warsh still has to explain at 2:30 why the Fed hiked in September and held now. SPY is +0.17% and QQQ +0.15% as of 2:05 PM ET.
Oil kept climbing (USO +2.8%) and the 10-year yield sat near 5.02% (CNBC). Earnings did the damage at the single-stock level: F5 -19.6% on a slower growth outlook despite a beat, Enphase -17.2%, Robinhood -4.0%. Vertiv +14.6% is the AI-infrastructure name that paid.
|
|
TODAY'S TOP 5 GAINERS
1 · ULBI +145.9% · $15.64. EnerSys agreed to buy Ultralife for $16.00 a share in cash (Business Wire Oct 27 4:31 PM ET). Deal stock, about 36 cents under the offer. ENS is -1.8%.
2 · BOOM +40.4% · $7.51. DMC Global posted Q3 adjusted EPS of 48 cents vs 10 cents expected (The Fly Oct 27 4:23 PM ET). Real beat on a ~$153M company.
3 · LUNG +33.3% · $2.64. Pulmonx returned to revenue growth, Q3 $22.8M vs $21.9M expected, and Stifel lifted its target to $4. Small cap, but the numbers are there.
4 · GMAB +32.1% · $59.00. Genmab's Phase 3 LiGeR-HN1 trial cut the risk of death 50% in first-line head and neck cancer. A ~$36B company at an all-time high. The move of the day.
5 · AXGN +28.6% · $48.18. Axogen Q3 revenue rose 26% to $75.8M, adjusted EPS 21 cents vs 13 cents, and it raised 2026 guidance to at least $290M (GlobeNewswire 7:02 AM ET).
|
|
THE SIGNAL
The Fed held, and the market is pricing the next hike anyway. That leaves earnings to carry stocks, and money is paying for proof. Memory chips with a supplier's profit print behind them got the bid while the AI spenders drifted lower ahead of their own numbers. Exposed: Microsoft and Alphabet, which now have to show cloud growth that justifies the capex with the 10-year near 5% and a December hike near 85% priced.
Wrong if: Warsh signals no December hike and yields drop, or Microsoft and Alphabet both rally after hours on capex raises without faster cloud growth.
|
|
HEADLINE OF THE DAY
“Federal Reserve keeps rates steady”
CNBC | Oct 28, 2:00 PM ET
The hold was expected. What matters is the roughly 85% odds of a December hike now in futures, with PCE inflation due Thursday morning.
|
|
ONE TO WATCH
MSFT (Microsoft) reports Q3 after today's close, alongside Alphabet (Reuters). Last $527.22, -0.77% as of 2:05 PM ET. Chips rallied on SK Hynix while the AI spenders slipped, so Microsoft's Azure growth and its capex number decide which side was right. A big capex lift without faster cloud growth is the bad mix.
|
|
HANDPICKED FOR YOU
|
|
SHH. THIS IS A CLUB.
You get the close because you open and click. Go quiet and we give your chair away.
|
|
|
Market Signal Report
powered by StocksToTrade
|
|
Signal over noise. Late-session read, not the official close. Full recap after the bell.
|